As described above, mutations in TP53 are common in cold tumors and are associated with resistance to chemotherapy, particularly temozolomide (TMZ), the standard-of-care treatment for GBM [26], as the loss of function mutation in TP53 enables the tumor cells to evade apoptosis. Here, TP53 is linked to glioblastoma.